Seed to Series B fund research profile
Chiratae is a home-grown Indian technology investor that evolved from IDG Ventures India into a multi-fund platform spanning seed, early growth and selective deeptech. Its public record links early positions in Flipkart, FirstCry, Lenskart and PolicyBazaar with newer bets in deeptech, healthcare and climate.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Chiratae Ventures uses a seed to series b approach across Consumer, health, deeptech, fintech.
Current evidence
Chiratae announced the second close of its fifth VC fund at $150M and later launched its Sonic DeepTech program, with named portfolio evidence including Lenskart, Curefoods, Uniphore and PolicyBazaar.
Strategy
Seed to Series B
Sector focus
Consumer, health, deeptech, fintech
AIF structure context
Indian venture capital and angel-fund strategies are commonly structured as Category I AIFs. Verify the specific vehicle and registration before investing.
Current signal
Chiratae announced the second close of its fifth VC fund at $150M and later launched its Sonic DeepTech program, with named portfolio evidence including Lenskart, Curefoods, Uniphore and PolicyBazaar.
Investor questions
Chiratae Ventures is covered in Rupeia's venture capital research universe. The current public record describes the strategy as Seed to Series B, with a sector focus of Consumer, health, deeptech, fintech. The profile should be read with the linked source trail and Typical route: Category I AIF context.
The profile displays only company or asset names attributable to Chiratae Ventures in the reviewed public sources: Lenskart (early), Curefoods, Uniphore, PolicyBazaar (early). It does not represent a complete current portfolio unless the manager has published one.
The GP says it manages $1.3B across seven funds, has made 135+ investments, achieved 60 exits and five IPOs. Inc42 separately reported 50+ exits and a highest exit of nearly 43x; these are manager-level or reported portfolio outcomes, not a verified net IRR for Fund V. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Fund IV closed at $337M in 2021. Fund V announced a $150M second close in 2024; the final close and target remain unconfirmed in the reviewed record.. Public terms or access information: Seed through Series B technology investing, with Chiratae Sonic as a seed initiative. The GP describes a thesis-led approach across consumer, SaaS, mobility, fintech, health and deeptech; India cheque sizes are not consistently disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Sudhir Sethi, TCM Sundaram, Venkatesh Peddi. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review stage concentration, follow-on reserves, company failure rates, dilution, exit timing and the gap between paper valuations and realised distributions. The current open diligence point is: Fund V final close confirmation.
2025-09-23: Chiratae announced the second close of its fifth VC fund at $150M and later launched its Sonic DeepTech program, with named portfolio evidence including Lenskart, Curefoods, Uniphore and PolicyBazaar.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.